Why the study?
CYP2C19*1 confers normal clopidogrel metabolism while CYP2C19*2 is a non-functional allele, prompting evaluation of genotype frequencies in Turkish patients with CAD and healthy controls.
This study aims to determine the prevalence of clopidogrel-metabolizing CYP2C19 alleles in a Turkish population with stable CAD compared to healthy controls.
Provides Turkish CYP2C19 genotype frequencies in CAD; leaves open clopidogrel personalization pending outcome data.
Objective: The CYP2C19*1 has an entirely normal activity allele whose clopidogrel metabolism is normal. CYP2C19*2 called as non-functional alleles. In this study, we aimed to establish the CYP2C19*1 and CYP2C19*2 genotype frequencies both in Turkish patients with coronary artery disease (CAD), who used clopidogrel, and in healthy Turkish population as well as to present the differences in genotypes and alleles between both groups.
No takes yet. Share an insight, caveat, or question.
Sabırlı et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: